Banner
Home

'End of an Era' for Chemo in Non-Small Cell Lung Cancer Print E-mail
Written by FHI's Week in Review   
Monday, 04 June 2018 16:48
 
Liam Davenport reports for Medscape on June 03, 2018 that most patients with advanced non-small cell lung cancer (NSCLC) can now avoid having chemotherapy as a first-line treatment, after a large, randomized trial showed that immunotherapy with the programmed cell death ligand 1 (PD-L1) blocker pembrolizumab (Keytruda, Merck) is effective even in patients with minimal PD-L1 expression.
 
Read more in the current issue of Week in Review>> https://conta.cc/2xDXg5G
 
Last Updated on Monday, 04 June 2018 17:30
 


Banner
Website design, development, and hosting provided by
Netphiles